Literature DB >> 22294488

The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer.

Karina H Gravgaard1, Maria B Lyng, Anne-Vibeke Laenkholm, Rolf Søkilde, Boye Schnack Nielsen, Thomas Litman, Henrik J Ditzel.   

Abstract

Metastases are the major cause of cancer-related deaths, but the mechanisms of the metastatic process remain poorly understood. In recent years, the involvement of microRNAs (miRNAs) in cancer has become apparent, and the objective of this study was to identify miRNAs associated with breast cancer progression. Global miRNA expression profiling was performed on 47 tumor samples from 14 patients with paired samples from primary breast tumors and corresponding lymph node and distant metastases using LNA-enhanced miRNA microarrays. The identified miRNA expression alterations were validated by real-time PCR, and tissue distribution of the miRNAs was visualized by in situ hybridization. The patients, in which the miRNA profile of the primary tumor and corresponding distant metastasis clustered in the unsupervised cluster analysis, showed significantly shorter intervals between the diagnosis of the primary tumor and distant metastasis (median 1.6 years) compared to those that did not cluster (median 11.3 years) (p<0.003). Fifteen miRNAs were identified that were significantly differentially expressed between primary tumors and corresponding distant metastases, including miR-9, miR-219-5p and four of the five members of the miR-200 family involved in epithelial-mesenchymal transition. Tumor expression of miR-9 and miR-200b were confirmed using in situ hybridization, which also verified higher expression of these miRNAs in the distant metastases versus corresponding primary tumors. Our results demonstrate alterations in miRNA expression at different stages of disease progression in breast cancer, and suggest a direct involvement of the miR-200 family and miR-9 in the metastatic process.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22294488     DOI: 10.1007/s10549-012-1969-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  50 in total

Review 1.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

Review 2.  The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets.

Authors:  Ulrich H Weidle; Steffen Dickopf; Corinna Hintermair; Gwendlyn Kollmorgen; Fabian Birzele; Ulrich Brinkmann
Journal:  Cancer Genomics Proteomics       Date:  2018 Jan-Feb       Impact factor: 4.069

3.  Potential use of microRNA-200c as a prognostic marker in non-small cell lung cancer.

Authors:  Libo Si; Hui Tian; Weiming Yue; Lin Li; Shuhai Li; Cun Gao; Lei Qi
Journal:  Oncol Lett       Date:  2017-07-25       Impact factor: 2.967

4.  miR-200-containing extracellular vesicles promote breast cancer cell metastasis.

Authors:  Minh T N Le; Peter Hamar; Changying Guo; Emre Basar; Ricardo Perdigão-Henriques; Leonora Balaj; Judy Lieberman
Journal:  J Clin Invest       Date:  2014-11-17       Impact factor: 14.808

5.  Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models.

Authors:  Jessica Bockhorn; Aleix Prat; Ya-Fang Chang; Xia Liu; Simo Huang; Meng Shang; Chika Nwachukwu; Maria J Gomez-Vega; J Chuck Harrell; Olufunmilayo I Olopade; Charles M Perou; Huiping Liu
Journal:  Cancer Res       Date:  2014-10-22       Impact factor: 12.701

6.  The role of miR-200a in mammalian epithelial cell transformation.

Authors:  Lindsey E Becker; Apana Agha L Takwi; Zhongxin Lu; Yong Li
Journal:  Carcinogenesis       Date:  2014-09-19       Impact factor: 4.944

7.  Development and validation of a microRNA based diagnostic assay for primary tumor site classification of liver core biopsies.

Authors:  Katharina Perell; Martin Vincent; Ben Vainer; Bodil Laub Petersen; Birgitte Federspiel; Anne Kirstine Møller; Mette Madsen; Niels Richard Hansen; Lennart Friis-Hansen; Finn Cilius Nielsen; Gedske Daugaard
Journal:  Mol Oncol       Date:  2014-08-01       Impact factor: 6.603

8.  MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition.

Authors:  Jon S Zawistowski; Kazuhiro Nakamura; Joel S Parker; Deborah A Granger; Brian T Golitz; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2013-03-25       Impact factor: 4.272

Review 9.  SUMO and ischemic tolerance.

Authors:  Yang-ja Lee; John M Hallenbeck
Journal:  Neuromolecular Med       Date:  2013-06-18       Impact factor: 3.843

10.  MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas.

Authors:  Simon Kjær Hermansen; Rikke Hedegaard Dahlrot; Boye Schnack Nielsen; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2012-10-28       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.